论文部分内容阅读
目的探讨乳腺癌组织中C-erbB-2表达及其与Survivin、雌激素受体(ER)和孕激素受体(PR)表达的临床意义。方法用免疫组织化学染色SP法对76例乳腺癌组织中C-erbB-2、Survivin、ER和PR的表达结果进行分析。结果C-erbB-2在乳腺癌组织中的阳性率为70%,乳腺增生组为阴性表达,两者差异有统计学意义(P<0.05)。乳腺癌患者C-erbB-2表达在不同患者年龄、不同肿块大小之间差异无统计学意义(P>0.05),在不同乳腺癌组织学分级和有无淋巴结转移之间差异有统计学意义(P<0.05),且C-erbB-2表达与Survivin存在正相关(r=0.247,P<0.05)。结论乳腺癌组织中C-erbB-2表达上调与乳腺癌的发生、发展和预后密切相关,联合检测C-erbB-2、Survivin对于反映乳腺癌细胞恶性程度和判断预后具有重要的意义。
Objective To investigate the expression of C-erbB-2 in breast cancer and its clinical significance with the expression of Survivin, estrogen receptor (ER) and progesterone receptor (PR). Methods The expression of C-erbB-2, Survivin, ER and PR in 76 cases of breast cancer were analyzed by immunohistochemical SP method. Results The positive rate of C-erbB-2 in breast cancer tissues was 70%, while that in breast hyperplasia group was negative. The difference was statistically significant (P <0.05). There was no significant difference in the expression of C-erbB-2 in breast cancer patients between different age groups and different tumor sizes (P> 0.05). There was significant difference between different breast cancer histological grade and lymph node metastasis P <0.05). There was a positive correlation between the expression of C-erbB-2 and Survivin (r = 0.247, P <0.05). Conclusion The up-regulation of C-erbB-2 in breast cancer is closely related to the occurrence, development and prognosis of breast cancer. The combined detection of C-erbB-2 and Survivin is of great significance to reflect the malignant degree and prognosis of breast cancer.